MGX (Metagenomi) Common Stock : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Common Stock?

Metagenomi's quarterly common stock stayed the same from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) and stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

Metagenomi's annual common stock increased from Dec. 2021 ($0.57 Mil) to Dec. 2022 ($2.54 Mil) and increased from Dec. 2022 ($2.54 Mil) to Dec. 2023 ($9.46 Mil).

Metagenomi Common Stock Historical Data

The historical data trend for Metagenomi's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Common Stock Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Common Stock

0.57

2.54

9.46

Metagenomi Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial						6.99	9.46	-	-	-

Metagenomi Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, Emeryville, CA, USA, 94608

Website

https://www.metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).